Recruiting

Observational Study

Sponsor:

AstraZeneca

Code:

NCT07143110

Conditions

Lung Neoplasms

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

LUNG-ROLL is a retrospective cohort study that will describe the contemporary treatment patterns, prevalence and incidence, patient demographic and clinical characteristics, clinical outcomes, and healthcare resource use/costs for patients with lung cancer in Canada (specifically, Alberta and Ontario) using administrative data.

Conditions

Lung Neoplasms

Study ID

NCT07143110

Start date

Aug 20, 2025

Status verified date

Sep, 2026

Completion date

Sep 30, 2027

Anticipated

Primary completion date

Sep 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients with lung cancer between January 1, 2018 and end of the Selection Period.
  • Patient is 18 years of age or older on diagnosis date.
  • Patient has at least 12 months of health insurance coverage prior to the diagnosis date.

Exclusion Criteria:

  • Diagnosed with any other cancer in the 5-year period prior to January 1, 2018.
  • Diagnosed with any other cancer concurrently (i.e., on the same date) as lung cancer diagnosis.
  • Invalid or incomplete records for key variables (e.g., missing year of diagnosis, missing cancer type).
  • Non-Ontario or non-Alberta resident on diagnosis date.

Study Design

Enrollment

60000 participants

Anticipated

Interventions and Outcome Measures

Arms

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Primary outcome measure

  • Treatment patterns [ Time Frame: Through study completion, an average of 1 year ]

Central Contacts and Locations

Central contacts

AstraZeneca Clinical Study Information Center

1-877-240-9479information.center@astrazeneca.com

Locations

Research Site

Recruiting

Calgary, Alberta, Canada, T2N1N4

Research Site

Recruiting

Toronto, Ontario, Canada, M5T3M6

More Information

Sponsor

AstraZeneca

Last update posted

Sep 3, 2026

Last verified

Sep, 2026

Keywords

  • Lung Neoplasms
  • Non-Small-Cell Lung
  • Small Cell Lung
  • Epidemiology
  • Treatment Patterns
  • Real-World

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by AstraZeneca on 2026-09-03.